«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《内科》[ISSN:1006-6977/CN:61-1281/TN]

卷:

15卷

期数:

2020年06

页码:

665-668

栏目:

论著

出版日期:

2020-12-31

文章信息/Info

Title:

Efficacy of atorvastatin combined with tirofiban in the treatment of patients with ACS combined with arrhythmia and its influence on myocardial enzymes and inflammatory factors

文章编号:

1673-7768（2020）06-0665-04

作者:

胡晓亮; 朱永军; 张红威

商丘市第一人民医院心血管内三科，河南省商丘市476100

Author(s):

HU Xiaoliang;  ZHU Yongjun;  ZHANG Hongwei

The Third Department of Cardiovascular Medicine, Shangqiu First People′s Hospital, Shangqiu 476100, Henan province, China

关键词:

急性冠脉综合征; 心律失常; 阿托伐他汀; 替罗非班; 心肌酶谱; 炎症因子

Keywords:

Acute coronary syndrome;  Arrhythmia;  Atorvastatin;  Tirofiban;  Myocardial enzyme;  Inflammatory factor

分类号:

R 541.7

DOI:

DOI：10.16121/j.cnki.cn45-1347/r.2020.06.09

文献标志码:

A

摘要:

目的探讨阿托伐他汀联合替罗非班治疗急性冠状动脉综合征（ACS）伴心律失常患者的疗效及对患者心肌酶谱、炎症因子的影响。方法选择2018年1月至2019年9月我院收治的ACS伴心律失常患者96例，采用随机数字法分为两组，每组48例。两组患者均给予常规药物（阿托伐他汀等）及经皮冠脉介入（PCI）治疗；观察组患者在此基础上，在PCI术中、术后加用替罗非班治疗。比较两组患者的临床疗效；比较两组患者治疗前后的血清心肌酶谱及炎症因子水平；比较两组患者治疗期间的不良反应发生情况。结果治疗3个月，观察组患者的治疗总有效率（93.8%）显著高于对照组（79.2%），差异有统计学意义（P＜0.05）。治疗前，两组患者的血清肌酸激酶（CK）、肌酸激酶同工酶（CK-MB）、超敏C-反应蛋白（hs-CRP）、白细胞介素-6（IL-6）水平比较，差异无统计学意义（P＞0.05）；治疗3个月后，观察组患者的CK、CK-MB、hs-CRP、IL-6水平均显著低于对照组，差异有统计学意义（P＜0.05）。治疗期间两组患者的不良反应发生率比较差异无统计学意义（P＞0.05）。结论阿托伐他汀联合替罗非班治疗ACS伴心律失常患者疗效确切，可有效地抑制炎症反应，减轻心肌细胞损伤，治疗安全性高。

Abstract:

ObjectiveTo explore the efficacy of atorvastatin combined with tirofiban in the treatment of patients with acute coronary syndrome (ACS) combined with arrhythmia, and its influence on the myocardial enzymes and inflammatory factors. MethodsA total of 96 patients with ACS combined with arrhythmia admitted to our hospital from January 2018 to September 2019 were selected, and they were divided into two groups by the random number method, with 48 cases in each group. Both groups of patients were given conventional medicines (atovastatin etc.) and percutaneous coronary intervention (PCI) for treatment, based on which patients in the observation group were additionally treated with tirofiban during and after PCI. The clinical efficacy, the serum myocardial enzymes, and inflammatory factors levels before and after treatment, as well as the occurrence of adverse reactions during the treatment, were compared between the two groups. ResultsAfter 3 months of treatment, the total effective rate of treatment in the observation group (93.8%) was significantly higher than that in the control group (79.2%), and the difference was statistically significant (P＜0.05). The differences of the serum creatine kinase (CK), creatine kinase isoenzyme (CK-MB), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) levels between the two groups before treatment were not statistically significant (P＞0.05). After 3 months of treatment, the levels of CK, CK-MB, hs-CRP and IL-6 in the observation group were significantly lower than those in the control group, and the differences were statistically significant (P＜0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment period (P＞0.05). ConclusionAtorvastatin combined with tirofiban has a definite curative effect in the treatment of patients with ACS combined with arrhythmia, which can effectively inhibit inflammation, alleviate myocardial cell damage, and thus it is highly safe for treatment.

备注/Memo

备注/Memo:

▲基金项目：河南省科技攻关计划项目（201702333）

常用功能

更新日期/Last Update: 2021-01-11